(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 December 2008 (18.12.2008)

PCT

(10) International Publication Number
WO 2008/152390 A1

(51) International Patent Classification:
C07D 513/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:
PCT/GB2008/002014

(22) International Filing Date: 12 June 2008 (12.06.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0711344.2 12 June 2007 (12.06.2007) GB
0715677.1 10 August 2007 (10.08.2007) GB

(71) Applicant *(for all designated States except US)*: **F.HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HANCOX, Timothy, Colin** [GB/GB]; 957 Buckingham Avenue, Slough, Berkshire SL1 4NL (GB). **PEGG, Neil, Anthony** [GB/GB]; 957 Buckingham Avenue, Slough, Berkshire SL1 4NL (GB). **BESWICK, Mandy, Christine** [GB/GB]; 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR (GB). **BLENCH, Toby, Jonathan** [GB/GB]; 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR (GB). **DECHAUX, Elsa, Amandine** [FR/GB]; 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR (GB). **KULAGOWSKI, Janusz, Jozef** [GB/GB]; 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR (GB). **NADIN, Alan, John** [GB/GB]; 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR (GB). **PRICE, Stephen** [GB/GB]; 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR (GB).


(74) Agents: **KEEN, Celia, Mary** et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5JJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(54) Title: THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE



(I)



(IIa)

(57) Abstract: Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; R^1 and R^2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; R^3 is H or C_1-C_6 alkyl; and R^4 is an indole group which is unsubstituted or substituted; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PD kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

WO 2008/152390 A1